Refine
Year of publication
Language
- English (34)
Is part of the Bibliography
- yes (34)
Keywords
- ceramide (10)
- acid sphingomyelinase (9)
- acid ceramidase (5)
- Acid sphingomyelinase (3)
- Farber disease (3)
- Sphingolipids (3)
- lysosomal storage disorders (3)
- sphingomyelin (3)
- 1-aminodecylidene bis-phosphonic acid (2)
- Ceramide (2)
- Pseudomonas aeruginosa (2)
- Smpd1 (2)
- amitriptyline (2)
- anxiety-like behavior (2)
- bisphosphonates (2)
- cerami-des (2)
- ceramides (2)
- chronic psychosocial stress (2)
- chronic subordinate colony housing (CSC) (2)
- depressive-like behavior (2)
- enzymology (2)
- forebrain (2)
- functional inhibitors of acid sphin-gomyelinase (2)
- lipid metabolism (2)
- liver metabolism (2)
- lysosomal hydrolases (2)
- lysosome (2)
- mass spectrometry (2)
- serine palmitoyltransferase (2)
- sphingolipid de novo synthesis (2)
- sphingolipid metabolism (2)
- sphingolipids (2)
- stable-isotope labeling (2)
- (2E)-hexadecenal (1)
- (2E)-hexadecenoic acid (1)
- Acinetobacter baumannii (1)
- Adipose tissue (1)
- Akt (1)
- Alcohol dependence (1)
- Anxiety (1)
- Autotaxin (1)
- COPD (1)
- CXCR2 (1)
- Caenorhabditis elegans (1)
- Cardiovascular (1)
- Case-control study (1)
- Chemoprophylaxis (1)
- Clinical (1)
- Coating (1)
- Cystic fibrosis (1)
- DAIH (1)
- Depression (1)
- Derivatization (1)
- Diagnostic (1)
- Disease (1)
- Dopamine (1)
- EDC (1)
- Glycerophospholipids (1)
- HPLC-ESI-QTOF (1)
- Hepatic insulin resistance (1)
- Inhalation (1)
- Insulin signaling (1)
- Ischemia/reperfusion (1)
- Isotope-dilution (1)
- Isotope-dilution analysis (1)
- LPA(3) receptor subtype (1)
- Liquid chromatography-tandem mass spectrometry (1)
- Liver injury (1)
- Lysophosphatidic acid (1)
- Lysophosphatidylcholines (1)
- Mass spectrometry (1)
- PTEN (1)
- Phosphatidylcholines (1)
- Phosphatidylinositols (1)
- Plasma (1)
- Plasmalogens (1)
- Plastic surfaces (1)
- Serotonin (1)
- Sphingomyelin (1)
- Sphingosine (1)
- Sphingosine 1-phosphate (1)
- Sphingosine kinase (1)
- Staphylococcus aureus (1)
- Tandem mass spectrometry (1)
- Transplantation (1)
- Trauma (1)
- Traumatic brain injury (1)
- Venous thromboembolism (1)
- Ventilation (1)
- blood banking (1)
- burn injury (1)
- cystic fibrosis (1)
- dysfunction (1)
- extinction (1)
- hepatic ischemia-reperfusion (1)
- hippocampus (1)
- homolog (1)
- immune (1)
- injury (1)
- integrins (1)
- ischemia/reperfusion (1)
- liver-regeneration (1)
- long chain base (1)
- lung infection (1)
- lung inflammation (1)
- mechanisms (1)
- mice (1)
- microparticle (1)
- neutrophil (1)
- neutrophil chemotaxis (1)
- operant behavior (1)
- platelets (1)
- recovery (1)
- sphingosine (1)
- tumor-metastasis (1)
Ventilator-associated pneumonia (VAP) is a major cause of morbidity and mortality in critically ill patients. Here, we employed the broad antibacterial effects of sphingosine to prevent VAP by developing a novel method of coating surfaces of endotracheal tubes with sphingosine and sphingosine analogs. Sphingosine and phytosphingosine coatings of endotracheal tubes prevent adherence and mediate killing of Pseudomonas aeruginosa, Acinetobacter baumannii, and Staphylococcus aureus, even in biofilms. Most importantly, sphingosine-coating of endotracheal tubes also prevented P. aeruginosa and S. aureus pneumonia in vivo. Coating of the tubes with sphingosine was stable, without obvious side effects on tracheal epithelial cells and did not induce inflammation. In summary, we describe a novel method to coat plastic surfaces and provide evidence for the application of sphingosine and phytosphingosine as novel antimicrobial coatings to prevent bacterial adherence and induce killing of pathogens on the surface of endotracheal tubes with potential to prevent biofilm formation and VAP.Key messagesNovel dip-coating method to coat plastic surfaces with lipids.Sphingosine and phytosphingosine as novel antimicrobial coatings on plastic surface.Sphingosine coatings of endotracheal tubes prevent bacterial adherence and biofilms.Sphingosine coatings of endotracheal tubes induce killing of pathogens.Sphingosine coatings of endotracheal tubes ventilator-associated pneumonia.
Human and murine studies identified the lysosomal enzyme acid sphingomyelinase (ASM) as a target for antidepressant therapy and revealed its role in the pathophysiology of major depression. In this study, we generated a mouse model with overexpression of Asm (Asm-tg(fb)) that is restricted to the forebrain to rule out any systemic effects of Asm overexpression on depressive-like symptoms. The increase in Asm activity was higher in male Asm-tg(fb) mice than in female Asm-tg(fb) mice due to the breeding strategy, which allows for the generation of wild-type littermates as appropriate controls. Asm overexpression in the forebrain of male mice resulted in a depressive-like phenotype, whereas in female mice, Asm overexpression resulted in a social anxiogenic-like phenotype. Ceramides in male Asm-tg(fb) mice were elevated specifically in the dorsal hippocampus. mRNA expression analyses indicated that the increase in Asm activity affected other ceramide-generating pathways, which might help to balance ceramide levels in cortical brain regions. This forebrain-specific mouse model offers a novel tool for dissecting the molecular mechanisms that play a role in the pathophysiology of major depression.
Human and murine studies identified the lysosomal enzyme acid sphingomyelinase (ASM) as a target for antidepressant therapy and revealed its role in the pathophysiology of major depression. In this study, we generated a mouse model with overexpression of Asm (Asm-tg(fb)) that is restricted to the forebrain to rule out any systemic effects of Asm overexpression on depressive-like symptoms. The increase in Asm activity was higher in male Asm-tg(fb) mice than in female Asm-tg(fb) mice due to the breeding strategy, which allows for the generation of wild-type littermates as appropriate controls. Asm overexpression in the forebrain of male mice resulted in a depressive-like phenotype, whereas in female mice, Asm overexpression resulted in a social anxiogenic-like phenotype. Ceramides in male Asm-tg(fb) mice were elevated specifically in the dorsal hippocampus. mRNA expression analyses indicated that the increase in Asm activity affected other ceramide-generating pathways, which might help to balance ceramide levels in cortical brain regions. This forebrain-specific mouse model offers a novel tool for dissecting the molecular mechanisms that play a role in the pathophysiology of major depression.
Background: The pathophysiology behind the subacute but persistent hypercoagulable state after traumatic brain injury (TBI) is poorly understood but contributes to morbidity induced by venous thromboembolism. Because platelets and their microvesicles have been hypothesized to play a role in post-traumatic hypercoagulability, administration of commonly used agents may ameliorate this coagulability. We hypothesized that utilization of aspirin, ketorolac, amitriptyline, unfractionated heparin, or enoxaparin would modulate the platelet aggregation response after TBI. Methods: Concussive TBI was induced by weight drop. Mice were then randomized to receive aspirin, ketorolac, amitriptyline, heparin, enoxaparin, or saline control at 2 and 8 h after TBI. Mice were sacrificed at 6 or 24 h after injury to determine coagulability by rotational thromboelastometry (ROTEM), platelet function testing with impedance aggregometry, and microvesicle enumeration. Platelet sphingolipid metabolites were analyzed by mass spectrometry. Results: ROTEM demonstrated increased platelet contribution to maximum clot firmness at 6 h after TBI in mice that received aspirin or amitriptyline, but this did not persist at 24 h. By contrast, adenosine diphosphate- and arachidonic acid-induced platelet aggregation at 6 h was significantly lower in mice receiving ketorolac, aspirin, and amitriptyline compared with mice receiving saline at 6 h after injury and only arachidonic acid-initiated platelet aggregation was decreased by aspirin at 24 h. There were no differences in microvesicle production at either time point. Platelet sphingosine-1-phosphate levels were decreased at 6 h in the group receiving amitriptyline and increased at 24 h along with platelet ceramide levels at 24 h in the amitriptyline group. Conclusion: After TBI, amitriptyline decreased platelet aggregability and increased contribution to clot in a manner similar to aspirin. The amitriptyline effects on platelet function and sphingolipid metabolites may represent a possible role of the acid sphingomyelinase in the hypercoagulability observed after injury. In addition, inhibition of platelet reactivity may be an underappreciated benefit of low molecular weight heparins, such as enoxaparin. (C) 2019 Elsevier Inc. All rights reserved.